Chawla Sonam, Rahar Babita, Singh Mrinalini, Bansal Anju, Saraswat Deepika, Saxena Shweta
Experimental Biology Division, Defence Institute of Physiology and Allied Sciences, Defence Research and Development Organisation, Ministry of Defence, Lucknow Road, Timarpur, Delhi, India.
PLoS One. 2014 Jun 2;9(6):e98025. doi: 10.1371/journal.pone.0098025. eCollection 2014.
The physiological challenges posed by hypobaric hypoxia warrant exploration of pharmacological entities to improve acclimatization to hypoxia. The present study investigates the preclinical efficacy of sphingosine-1-phosphate (S1P) to improve acclimatization to simulated hypobaric hypoxia.
Efficacy of intravenously administered S1P in improving haematological and metabolic acclimatization was evaluated in rats exposed to simulated acute hypobaric hypoxia (7620 m for 6 hours) following S1P pre-treatment for three days.
Altitude exposure of the control rats caused systemic hypoxia, hypocapnia (plausible sign of hyperventilation) and respiratory alkalosis due to suboptimal renal compensation indicated by an overt alkaline pH of the mixed venous blood. This was associated with pronounced energy deficit in the hepatic tissue along with systemic oxidative stress and inflammation. S1P pre-treatment improved blood oxygen-carrying-capacity by increasing haemoglobin, haematocrit, and RBC count, probably as an outcome of hypoxia inducible factor-1α mediated erythropoiesis and renal S1P receptor 1 mediated haemoconcentation. The improved partial pressure of oxygen in the blood could further restore aerobic respiration and increase ATP content in the hepatic tissue of S1P treated animals. S1P could also protect the animals from hypoxia mediated oxidative stress and inflammation.
The study findings highlight S1P's merits as a preconditioning agent for improving acclimatization to acute hypobaric hypoxia exposure. The results may have long term clinical application for improving physiological acclimatization of subjects venturing into high altitude for occupational or recreational purposes.
低压缺氧带来的生理挑战促使人们探索能够改善对缺氧适应能力的药物实体。本研究调查了鞘氨醇-1-磷酸(S1P)在改善对模拟低压缺氧适应能力方面的临床前疗效。
在对大鼠进行为期三天的S1P预处理后,评估静脉注射S1P对暴露于模拟急性低压缺氧(7620米,6小时)的大鼠血液学和代谢适应能力改善的效果。
对照大鼠暴露于高原导致全身性缺氧、低碳酸血症(可能是过度通气的迹象)以及由于混合静脉血明显碱性pH值表明肾脏代偿不足而引起的呼吸性碱中毒。这与肝组织中明显的能量缺乏以及全身性氧化应激和炎症相关。S1P预处理通过增加血红蛋白、血细胞比容和红细胞计数提高了血液携氧能力,这可能是缺氧诱导因子-1α介导的红细胞生成和肾脏S1P受体1介导的血液浓缩的结果。血液中氧分压的改善可进一步恢复S1P处理动物肝组织中的有氧呼吸并增加ATP含量。S1P还可保护动物免受缺氧介导的氧化应激和炎症。
研究结果突出了S1P作为改善对急性低压缺氧暴露适应能力的预处理剂的优点。这些结果可能对改善出于职业或娱乐目的前往高海拔地区的受试者的生理适应能力具有长期临床应用价值。